1 / 32

Establish the NTCP Evaluation System for Radiotherapy

Establish the NTCP Evaluation System for Radiotherapy. 學生 : 蕭安成 指導老師 : 陳為立教授. The goal of radiotherapy.

alder
Download Presentation

Establish the NTCP Evaluation System for Radiotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Establish the NTCP Evaluation System for Radiotherapy 學生: 蕭安成指導老師: 陳為立教授

  2. The goal of radiotherapy • To deliver a sufficient dose to the tumor to provide a high probability of cure while inducing minimal damage in the surrounding normal tissues, leaving them architecturally intact and functionally competent.

  3. Radiotherapy treatment planning 1980’sConformal Therapy 1990’sIntensity Modulated Radiation Therapy (IMRT) • New treatment techniques drove the developers of models to evaluate the resultant complex dose distribution plans

  4. Radiotherapy treatment planning Tumor Control Probability (TCP) Normal Tissue Complication Probability (NTCP) DOSE

  5. CTV2 CTV2 CTV2 CTV2 CTV1 GTV GTV P P GTV P P GTV GTV SC CTV1 BSP CTV1 CTV1 CTV1 Fig 1 (a) Plan evaluation • Target and critical organ CTV2 SC Fig 1 (c)

  6. Plan evaluation • Geometric dose distribution Sequential-IMRT SIB-IMRT

  7. Plan evaluation • Dose-volume histogram (DVH) • DVHs obtained with two IMRT planning techniques for (left) CTV, (right) right parotid. SIB-IMRT: 1; sequential-IMRT: 2

  8. Plan evaluation • Dose-volume histogram • the location of high-dose or other regions cannot be determined from the DVHs • the geometric distribution of dose was irrelevant to its biological impact

  9. Plan evaluation • Biological indices • Normal tissue complication probability (NTCP) • Tumor control probability(TCP)

  10. Plan evaluation • The probability of uncomplicated tumor control (PUTC): PUTC=TCP(1-NTCP)

  11. Normal tissue complication probability • These models aim to predict the probability of a complication as a function of the dose or biologically equivalent dose and volume

  12. Normal tissue complication probability • Functionally, the whole organ does not fail if some part of it is destroyed • Withers suggested that the tolerance of tissues depends on the ability of the remaining clonogenic cells to maintain a sufficient number of mature cells suitably structured to maintain organ function

  13. Normal tissue complication probability • Organ function depend upon the aggregation of cells into functional sub-units ( FSUs ) • FSUs in an organ can be organized in series or parallel • Series: gastrointestinal tract and spinal cord, damage in one portion of the organ may produce total organ fail • Parallel: lung or kidney, function is often maintained since the undamaged part operates independently from the damage part

  14. Normal tissue complication probability • Volume dependence • A lot to a little or a little to a lot ? • Whether it is better to give a lot to a little as unconventional treatment, or a little to a lot as in 3D and IMRT

  15. Models for NTCP • Homogeneous dose distribution • Empirical model • Probit model : Lyman (1985) • Logistic model • Tissue architecture model • Inhomogeneous dose distribution • Effective dose method : Lyman and Wolbarst (1987) • Effective volume method : Kutcher and Burman (1989) • Integral probability model : Schultheiss et al. (1983)

  16. Probit model (Lyman) TD50(1) : the tolerance dose for reference volume irradiation m : the steepness slope of the dose response curve Vref : the reference volume n : tissue-specific parameter

  17. Tolerance Data: Emami et al., 1991Lung Vol 1/3 2/3 3/3 TD5/5 4500 3000 1750 TD50/56500 4000 2450 TD5/5 is the dose to the partial organ that would have a 5 % probability of complication in 5 years. TD50/5 is the dose to the partial organ that would have a 50 % probability of complication in 5 years.

  18. Fitting of Tolerance Data: Burman et al., 1991Lung, brainstem, optic nerve organ n m TD50 end point Lung 0.87 0.18 24.5 Pneumonitis Brainstem 0.16 0.14 65 necrosis/infarction Optic nerve 0.25 0.14 65 blindness TD5/5 TD50/5 organ 1/3 2/3 1 1/3 2/3 1 Lung 45 30 17.5 65 40 24.5 (fitted data) 45 24 17 64 35 25 Brainstem 60 53 50 - - 65 (fitted data)60 53 50 65 Optic nerve - - 50 - - 65 (fitted data)- - 50 - - 65

  19. NTCP vs. dose, fixed partial irradiated volume 2/3 3/3 3/3 2/3 NTCP NTCP 1/3 1/3 dose dose Large volume effect, n  1.0 small volume effect, n  0.0

  20. NTCP vs. partial irradiated volume, fixed dose NTCP NTCP threshold volume TD50 TD20 TD50 TD20 TD5 TD5 Partial volume Partial volume Threshold volume, below which there is no complication No threshold volume, any volume irradiated contributes to complication

  21. Partial irradiated volume vs. dose, fixed NTCP NTCP=50% 20% Partial volume Partial volume 5% dose dose Large volume effect, n  1.0 small volume effect, n  0.0

  22. Logistic model γ50 D50 : the dose resulting in a 50% complication probability for some specified complication or end point k : 4γ50D50 (γ50 : slope of D50) D50

  23. Lyman model or logistic model Effective dose method DN’ From Lyman et al. 1987

  24. Lyman model or logistic model Effective volume method From Kutcher et al.1989

  25. Clinical application • Application software program for NTCP evaluation • Biological evaluation for four different radiation techniques for left side breast cancer: (1) 3-dimensional tangential plan (3D) (2) 2-field tangential IMRT plan (2T) (3) 2-field optimized IMRT plan (2O) (4) 4-field IMRT plan (4I)

  26. Clinical application

  27. Clinical application

  28. Clinical application

  29. Clinical application

  30. Clinical application

  31. Clinical application

  32. THANK YOU !!

More Related